DE69526521T2 - Modulation der immunantwort - Google Patents

Modulation der immunantwort

Info

Publication number
DE69526521T2
DE69526521T2 DE69526521T DE69526521T DE69526521T2 DE 69526521 T2 DE69526521 T2 DE 69526521T2 DE 69526521 T DE69526521 T DE 69526521T DE 69526521 T DE69526521 T DE 69526521T DE 69526521 T2 DE69526521 T2 DE 69526521T2
Authority
DE
Germany
Prior art keywords
molecules
immunogen
administration
immune response
ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69526521T
Other languages
English (en)
Other versions
DE69526521D1 (de
Inventor
Thomas Fearon
Walter Dempsey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge University Technical Services Ltd CUTS
Original Assignee
Cambridge University Technical Services Ltd CUTS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge University Technical Services Ltd CUTS filed Critical Cambridge University Technical Services Ltd CUTS
Publication of DE69526521D1 publication Critical patent/DE69526521D1/de
Application granted granted Critical
Publication of DE69526521T2 publication Critical patent/DE69526521T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Optical Communication System (AREA)
  • Amplifiers (AREA)
  • Steroid Compounds (AREA)
  • Holo Graphy (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69526521T 1994-12-06 1995-12-06 Modulation der immunantwort Expired - Fee Related DE69526521T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9424631A GB9424631D0 (en) 1994-12-06 1994-12-06 Modulating the immune response
PCT/GB1995/002851 WO1996017625A1 (en) 1994-12-06 1995-12-06 Modulating the immune response

Publications (2)

Publication Number Publication Date
DE69526521D1 DE69526521D1 (de) 2002-05-29
DE69526521T2 true DE69526521T2 (de) 2002-12-05

Family

ID=10765518

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69526521T Expired - Fee Related DE69526521T2 (de) 1994-12-06 1995-12-06 Modulation der immunantwort

Country Status (12)

Country Link
US (2) US6238670B1 (de)
EP (1) EP0797452B1 (de)
JP (1) JPH10509723A (de)
AT (1) ATE216593T1 (de)
AU (1) AU709990B2 (de)
CA (1) CA2207000A1 (de)
DE (1) DE69526521T2 (de)
DK (1) DK0797452T3 (de)
ES (1) ES2176347T3 (de)
GB (1) GB9424631D0 (de)
PT (1) PT797452E (de)
WO (1) WO1996017625A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9708387A (pt) 1996-03-28 2000-01-04 Genitrix Llc Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
CA2297786C (en) * 1997-08-05 2011-06-14 Vlaams Interuniversitair Instituut Voor Biotechnologie New immunoprotective influenza antigen and its use in vaccination
US7569674B2 (en) 1998-05-04 2009-08-04 Innexus Biotechnology International Limited Autophilic antibodies
GB9727512D0 (en) * 1997-12-31 1998-02-25 Adprotech Plc Fuzzy genes and their application in molecular adjuvants
WO1999064603A2 (en) * 1998-06-12 1999-12-16 Henry M. Jackson Foundation For The Advancement Of Military Medicine ENHANCEMENT OF B CELL ACTIVATION AND IMMUNOGLOBULIN SECRETION BY CO-STIMULATION OF RECEPTORS FOR ANTIGEN AND EBV Gp350/220
US20050244954A1 (en) * 1998-06-23 2005-11-03 Blackburn Gary F Binding acceleration techniques for the detection of analytes
EP1001021B1 (de) 1998-09-25 2003-08-27 Wolfgang Prodinger Monoklonaler Antikörper gegen das humanen CD21 und dessen Verwendungen
GB0008582D0 (en) * 2000-04-08 2000-05-31 Adprotech Plc DNA immunization vectors
WO2001092295A2 (en) * 2000-05-30 2001-12-06 University Of Toronto Ligands for cd21 and compositions thereof for modulating immune responses
GB0025229D0 (en) * 2000-10-14 2000-11-29 Adprotech Ltd Veterinary immunisation vectors
WO2002092011A2 (en) * 2001-05-17 2002-11-21 La Jolla Pharmaceutical Company Methods of treating antibody-mediated pathologies using agents which inhibit cd21
GB0204154D0 (en) * 2002-02-22 2002-04-10 Adprotech Ltd Cat immunisation vectors
JP2006505252A (ja) * 2002-08-14 2006-02-16 アヴィディス エスアー 抗原およびアジュバントの多量体複合体
JP2004222435A (ja) * 2003-01-16 2004-08-05 Fuji Heavy Ind Ltd 電気自動車の駆動装置
US9475853B2 (en) 2012-01-19 2016-10-25 Albany Medical College Fusion protein for enhancing immunogenicity of bacterial antigen/immunogen
EP2827889A1 (de) 2012-03-19 2015-01-28 Deutsches Krebsforschungszentrum B-zell-rezeptorkomplexbindendende proteine mit t-zell-epitopen
EP2674168A1 (de) * 2012-06-14 2013-12-18 PLS-Design GmbH Modulation von Effektor-T-Zell-Antworten durch lokale Depletion des Komplement-Faktors C3
WO2014006063A2 (en) 2012-07-02 2014-01-09 Medizinische Universität Wien Complement split product c4d for the treatment of inflammatory conditions
US20200262879A1 (en) 2017-09-11 2020-08-20 Insideoutbio, Inc. Methods and compositions to enhance the immunogenicity of tumors
US20210403519A1 (en) 2018-11-02 2021-12-30 Insideoutbio, Inc. Methods and compositions to induce or suppress immune responses through the use of membrane bound complement split products

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
CA2023779A1 (en) * 1989-08-23 1991-02-24 Margaret D. Moore Compositions and methods for detection and treatment of epstein-barr virus infection and immune disorders
US5331090A (en) * 1989-09-08 1994-07-19 California Institute Of Biological Research CR2 ligand compositions and methods for modulating immune cell functions
AU7566991A (en) * 1990-03-14 1991-10-10 Biomembrane Institute, The Monoclonal antibody and immunoconjugates for the treatment and detection of b cell disorders
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
ES2053413T3 (es) * 1992-05-14 1997-11-16 Polymun Scient Immunbio Forsch Peptidos que inducen anticuerpos que neutralizan aislados de vih-1 geneticamente divergentes.

Also Published As

Publication number Publication date
PT797452E (pt) 2002-10-31
EP0797452B1 (de) 2002-04-24
CA2207000A1 (en) 1996-06-13
ATE216593T1 (de) 2002-05-15
DE69526521D1 (de) 2002-05-29
GB9424631D0 (en) 1995-01-25
JPH10509723A (ja) 1998-09-22
EP0797452A1 (de) 1997-10-01
US6238670B1 (en) 2001-05-29
WO1996017625A1 (en) 1996-06-13
AU4120496A (en) 1996-06-26
US6891027B2 (en) 2005-05-10
AU709990B2 (en) 1999-09-09
DK0797452T3 (da) 2002-08-19
US20020102656A1 (en) 2002-08-01
ES2176347T3 (es) 2002-12-01

Similar Documents

Publication Publication Date Title
DE69526521D1 (de) Modulation der immunantwort
DE68924850D1 (de) Heterofunktionelle zellular immunologische reagenzien, impfstoffe daraus und verwendungsverfahren.
ATE47155T1 (de) Monoklonaler antikoerper.
DK338587D0 (da) Modulsamling af antistofgener, antistoffer fremstillet derved samt anvendelse deraf
ATE87655T1 (de) Markierer der t-zelle aktivierung.
NO20003716D0 (no) Protein D for anvendelse in vitro, renset antistoff som binder proteinet, samt anvendelser derav
RU94024561A (ru) Иммунореактивные композиции, способ получения композиции, способы получения и обнаружения антител, набор днк, клетка-хозяин, способ получения белка
IE811595L (en) Synthetic peptide antigens
RU93058563A (ru) Полипептиды, иммунореагент, способ определения антител, способ индукции иммунного ответа, композиции, способ получения полипептида
AU3900589A (en) Antigenic constructs of major histocompatibility complex class 1 antigens with specific carrier molecules, the preparation and use thereof
ES2181734T3 (es) Ensayo inmunologico de ciclosporina.
SE9103183L (sv) Virus-antikroppskomplex
ATE71411T1 (de) Monoklonale antikoerper mit spezifitaet fuer membran-assoziierte antigene.
WO1998025958A3 (en) Mammalian cell surface antigens comprising structural motifs characteristic of a member of the TNF ligand family
OA08485A (fr) Monoclonal antibodies and antigen for human non-small cell lung carcinoma and certain other human carcinomas.
IT8720842A0 (it) Analisi immunologiva stratificata impiegando anticorpi legati a particelle di trasporto per determinare la presenza di un antigene.
ATE74662T1 (de) Immunoanalysetestverfahren fuer cholesterolepoxide.
IT7920592A0 (it) Determinazione di antigeni oppure di anticorpi.
EP0363109A3 (de) Bestimmung eines chlamydialen oder gonokokkalen Antigens unter Verwendung eines positiv geladenen ionischen Bindungsträgers
EP0248534A3 (de) Verfahren zum Nachweis einer AIDS-Virus-Infektion
DE69133185D1 (de) Entwicklung von dns-sonden und immunologischen reagenzien von menschlichen tumor-assoziierten antigenen
DE3888437T2 (de) Immobilisierte Antikörper.
ATE87941T1 (de) Monoklonaler antikoerper gegen ein p21-bezuegliches dodekapeptid des ras-onkogens.
DK528279A (da) Fremgangsmaade til isolering af hepatitis b e antigen eller antistof
JPS5386014A (en) Quantitative analysis of antigen and antibody

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee